<DOC>
	<DOCNO>NCT02867735</DOCNO>
	<brief_summary>To evaluate safety tolerability LKA651 patient macular edema diabetic macular edema ( DME ) , neovascular age-related macular degeneration ( AMD ) , retinal vein occlusion ( RVO )</brief_summary>
	<brief_title>A Study Assess Safety , Tolerability , Pharmacokinetics Pharmacodynamic Activity Intravitreal LKA651 Patients With Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Patients macular edema center involvement least one eye , include focal diffuse DME , neovascular AMD , RVO The ETDRS letter score study eye must 60 letter bad ( approximate Snellen equivalent 20/63 ) Vital sign specify within protocol Proliferative diabetic retinopathy study eye , exception tuft neovascularization le one disc area vitreous hemorrhage Patient , type 1 type 2 diabetes hemoglobin A1C &gt; = 12 % screen ocular condition specify protocol systemic condition specify protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Macular Edema</keyword>
	<keyword>Diabetic Macular Edema ( DME )</keyword>
	<keyword>Neovascular age-related Macular Degeneration ( AMD )</keyword>
	<keyword>Retinal Vein Occlusions ( RVO )</keyword>
</DOC>